Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis
| Autor: | Onofre Moran Mendoza, Sharina Aldhaheri, Lynda Mccarthy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Drug
Lung business.industry media_common.quotation_subject Pirfenidone Disease respiratory system medicine.disease respiratory tract diseases Discontinuation chemistry.chemical_compound Idiopathic pulmonary fibrosis medicine.anatomical_structure Nursing chemistry medicine Nintedanib business Adverse effect medicine.drug media_common |
| Zdroj: | Idiopathic interstitial pneumonias. |
| Popis: | Background: Idiopathic pulmonary fibrosis (IPF) is fatal, progressive fibrosing, lung disease of unknown cause. Anti-fibrotic drugs can slow down the progression of the disease and reduce mortality. However, discontinuation rates of 19-21% have been reported for Pirfenidone and Nintedanib. No studies have assessed the impact of an ILD Nurse on the compliance to anti-fibrotic drugs. Objective: Assess the impact of an ILD Nurse on the compliance to anti-fibrotic drugs in IPF patients. Methods: We collected the information of anti-fibrotic drugs for patients diagnosed with IPF in our ILD clinic between during the period an ILD Nurse was hired: January, 2015 to December, 2017. We assessed the compliance of patients on Pirfenidone and Nintedanib. Results: There were 59 patients started on either Pirfenidone or Nintedanib. Mean treatment duration was 14 months (min. 1 month-max. 2.5 years). At the end of the study 53 patients (90%) were still on anti-fibrotics; 43 of them (81%) were on the full dose either drug and 10 (19%) were on a reduced dose. Of the 59 patients on anti-fibrotics, 45 were initially on Pirfenidone and 8 (18%) had to be switched to Nintedanib because of side effects. Of 14 patients initially on Nintedanib one (7%) had to be switched to Pirfenidone due to side effects. Discontinuation of antifibrotics occurred in only 10% of all patients. None of the 17 IPF patients started on antifibrotics during 2017 discontinued Pirfenidone (9 patients) or Nintedanib (8 patients). Conclusion: Having an ILD Nurse improves significantly compliance and reduced discontinuation rates due to adverse events to anti-fibrotics in patients with IPF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|